Prevymis FDA Approval History
FDA Approved: Yes (First approved November 8, 2017)
Brand name: Prevymis
Generic name: letermovir
Dosage form: Tablets and Injection
Company: Merck
Treatment for: CMV Prophylaxis
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.
Development timeline for Prevymis
| Date | Article |
|---|---|
| Nov 9, 2017 | Approval FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
